Loading company…
NeoImmuneTech develops clinical-stage treatments focused on T cells and immuno-oncology.
Founded in 2014, NeoImmuneTech is a biotechnology company developing clinical-stage treatments focused on T cells and immuno-oncology. Its product NT–17 is a T cell amplifier based on IL-7 and is studied in immuno-oncology and infectious disease. Based in Rockville, US, the company raised KRW 147.5 billion in venture funding in December 2018 from KB Investment and Mirae Asset Venture Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in